Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ❌ Debt failed
- ✅ P/E passed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 20.23%
Price change 2019 → 2020: -33.87%
Price change 2020 → 2021: -2.39%
Price change 2021 → 2022: 2.83%
Price change 2022 → 2023: -30.42%
Price change 2023 → 2024: -42.58%
Price change 2024 → 2025: 91.66%
Price change 2025 → 2026: 34.53%
Price change 2026 (year to date): 31.20%
Financial growth
Revenue CAGR (8 years): 3.13%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 1.44
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 10.30
P/E < 25.0 (maximum threshold).
Correction (6 months)
Current correction: 6.69% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="BAYN.DE" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Bayer AG | 11.5 | 1.44 | +1.8 % | 🔒 |
| Boston Scientific Corporation | 13.8 | 0.51 | +6.5 % | – |
| Cencora, Inc. | 19.4 | 7.13 | +9.6 % | – |
| Becton, Dickinson and Company | 16.3 | 0.76 | +6.5 % | – |
| Lonza Group AG | 41.6 | 0.50 | +6.1 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Bayer Aktiengesellschaft over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 45.6 bn | -11.6 bn | -25.4 % | n/a |
| 2021 | 48.6 bn | 1.1 bn | 2.3 % | +6.5 % |
| 2022 | 55.9 bn | 4.6 bn | 8.2 % | +15.1 % |
| 2023 | 52.5 bn | -3.2 bn | -6.2 % | -6.1 % |
| 2024 | 51.4 bn | -2.8 bn | -5.5 % | -2.2 % |
| 2025 | 50.2 bn | -4.0 bn | -7.9 % | -2.2 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Bayer Aktiengesellschaft over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 7.7 bn | 10.2 bn | 10.6 bn | 8.1 bn | 7.9 bn |
| Total Debt | 39.5 bn | 41.6 bn | 44.8 bn | 40.7 bn | 37.4 bn |
| Net Debt | 35.0 bn | 36.5 bn | 38.9 bn | 34.6 bn | 30.8 bn |
| Equity | 33.0 bn | 38.8 bn | 32.9 bn | 31.9 bn | 25.9 bn |
| Total assets | 120 bn | 125 bn | 116 bn | 111 bn | 111 bn |
| Operating cash flow | 5.1 bn | 7.1 bn | 5.1 bn | 7.4 bn | 4.6 bn |
| Investments (capex) | 2.6 bn | 2.9 bn | 2.8 bn | 2.8 bn | 2.5 bn |
| Free cash-flow | 2.5 bn | 4.1 bn | 2.4 bn | 4.6 bn | 2.1 bn |
| Share buybacks | 0 | 0 | 24.0 m | 16.0 m | 14.0 m |
| Dividends paid | 2.0 bn | 2.0 bn | 2.4 bn | 131 m | 127 m |
Amounts in EUR, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.
Valuation and competitors
Bayer Aktiengesellschaft compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Bayer Aktiengesellschaft | 60.9 bn | 11.5 | -7.9 % |
| Merck KGaA MRK.DE | 72.1 bn | 17.7 | 12.4 % |
| BASF Se BAS.DE | 52.2 bn | 28.2 | 2.7 % |
| Dermapharm Holding SE DMP.DE | 2.1 bn | 14.0 | 11.4 % |
| DSM-Firmenich AG DSFIR.AS | 29.9 bn | n/a | -12.0 % |
| Novartis AG NOVN.SW | 306 bn | 19.4 | 25.6 % |
| Sector median (Xetra) | 32.5 |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 16/11/2026. Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering Bayer Aktiengesellschaft publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Analyst forecasts
| Fiscal year | Revenue | Net income | Expected EPS (range) | P/E on this EPS | Analysts |
|---|---|---|---|---|---|
| 2026 | 45.8 bn | 4.5 bn | 4.51 (4.36 / 4.71) | 12.3 | 12 |
| 2027 | 47.1 bn | 4.8 bn | 4.79 (4.55 / 5.42) | 11.6 | 12 |
| 2028 | 48.6 bn | 5.3 bn | 5.36 (4.21 / 6.97) | 10.4 | 9 |
Amounts in EUR, the reporting currency.
Track record against expectations: reported EPS above consensus 10 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
Bayer Aktiengesellschaft: dividend history, last distributions, stock splits and earnings releases.
Annual dividend per share (EUR), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.
Latest ex-dividend dates
| Ex-dividend | Amount | Payment |
|---|---|---|
| 27/04/2026 | 0.110 EUR | 29/04/2026 |
| 28/04/2025 | 0.110 EUR | 30/04/2025 |
| 29/04/2024 | 0.110 EUR | 02/05/2024 |
| 02/05/2023 | 2.40 EUR | 04/05/2023 |
| 02/05/2022 | 2.00 EUR | 04/05/2022 |
| 28/04/2021 | 2.00 EUR | 30/04/2021 |
| 29/04/2020 | 2.80 EUR | 04/05/2020 |
| 29/04/2019 | 2.80 EUR | 02/05/2019 |
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 03/11/2026 | 0.31 | 0.39 | -19.9 % |
| 04/08/2026 | 0.94 | 0.76 | +23.0 % |
| 12/05/2026 | 2.69 | 2.30 | +17.0 % |
| 04/03/2026 | 0.63 | 0.39 | +60.7 % |
| 10/11/2025 | 0.58 | 0.37 | +55.7 % |
| 06/08/2025 | 1.24 | 0.91 | +36.6 % |
Stock splits
| Date | Operation |
|---|---|
| 06/06/2018 | split: 127 shares for 125 |
| 03/06/1996 | split: 10 shares for 1 |
Factual data: ex-dividend history and earnings calendar, as of 15/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Bayer Aktiengesellschaft.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 07/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Bayer Aktiengesellschaft
What is the Bayer Aktiengesellschaft share price?
Latest recorded price: 56.52 EUR on 13/11/2026, for a market cap of 61.2 bn USD.
What is the revenue of Bayer Aktiengesellschaft?
50.2 bn USD for fiscal year 2025, with net income of -4.0 bn USD (net margin -7.9 %).
Does Bayer Aktiengesellschaft pay a dividend?
Yes. Latest dividend: 0.110 EUR per share, ex-dividend on 27/04/2026. Over 12 months: 0.110 EUR. Yield on the latest known price: 0.3 %.
When does Bayer Aktiengesellschaft report its next earnings?
The next release is expected on 24/02/2027. EPS expected by analysts: 0.60.
What do analysts say about Bayer Aktiengesellschaft?
Out of 3 analysts: 1 buy or strong buy, 2 hold, 0 sell or strong sell.
What is the P/E ratio of Bayer Aktiengesellschaft?
Trailing 12-month P/E of 11.7, against 32.5 for the sector median on the same exchange (10-year median: 26.9).
Is Bayer Aktiengesellschaft stock eligible for the French PEA?
Likely: the company is headquartered in the European Union or the European Economic Area (ISIN DE000BAY0017) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.
How many employees does Bayer Aktiengesellschaft have?
90,587 full-time employees according to the latest published profile.
Who runs Bayer Aktiengesellschaft?
William N. Anderson is the company's chief executive.